Acc2014 6

• 1. Date of preparation April 2014 BRI001081ACC.14Annual ScientificSessions of theAmerican College ofCardiologyWashington DC29-31 March 2014

2. Date of preparation April 2014 BRI001081Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedACC.14, compiled by an external medical writer and sponsored by AstraZeneca. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights. 3. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014AleCardio study: Aleglitazar after ACSin type 2 diabetesCommentary:Associate Professor John AthertonRoyal Brisbane and Womens HospitalLate-breaking trial 4. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 5. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Published online in JAMA 6. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 7. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 8. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 9. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 10. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 11. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Improved HbA1c, TG, HDL-C 12. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014No improvement in CV outcomes 13. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Increased heartfailure (trend),weight gain 14. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Increased creatinine(reversible), fractures(trend), GI haemorrhage 15. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 16. Commentary: Associate Professor John AthertonDate of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 Early termination of the AleCardio trial due to futilityidentified that despite reductions in HbA1c and triglyceridescoupled with increases in HDL-cholesterol, there was noeffect on cardiovascular outcomes. Furthermore, there were increased side effects from thisPPAR / agonist, including weight gain, heart failure, renaldysfunction, bone fractures and GI haemorrhage . The results of the study are likely to discourage furtherdevelopment of this class of glucose-lowering therapies.